



iCARDIO Alliance Global Implementation Guidelines on Ischemic Heart Disease 2026

Fausto J. Pinto* (Portugal), Martha Gulati*(USA), Daniel Caldeira* (Portugal), Clara K. Chow (Australia), Luis Henrique Wolff Gowdak (Brazil), Dipti Itchhaporia (USA), Abdulla Shehab (UAE), Gurpreet Singh Wander (India), Beth L. Abramson (Canada), Takashi Akasaka (Japan), Giuseppe Ambrosio (Italy), Alexandra Arias-Mendoza (Mexico), Otavio Berwanger (UK), Anastase Dzudie (Cameroon), Evangelos Giannitsis (Germany), Rania Hammami (Tunisia), Neil Johnson (Ireland), Vijay Kunadian (UK), Renato D. Lopes (USA), Athanasios Manolis (Greece), Girish Mathur (India), Giuseppe M.C. Rosano (Italy), Ana Salvati (Argentina), Gregg W. Stone (USA), Jean-Claude Tardif (Canada), Ping Xie (China), Jian Zhang (China), Mohammad Zubaid (Kuwait), William T. Abraham (USA), Wael Abuzeid (Canada), Rasha Al-Bawardy (Saudi Arabia), Thomas Alexander (India), Stefan D. Anker (Germany), John J. Atherton (Australia), Andrea Baer (USA), Rakesh Bhadade (India), William E. Boden (USA), Gabriela Borraro Sanchez (Mexico), Javed Butler (USA), Edina Cenko (Italy), Edith H. Chavez (Peru), Vijay Chopra (India), Andrew J.S. Coats (Australia), Marcelo Di Carli (USA), Jianzeng Dong (China), Jan Fedacko (Slovakia), Gerasimos Filippatos (Greece), Abdoul Kane (Senegal), Muhammad Shahzeb Khan (USA), Pablos Lamelas (Argentina), Michael Lee (Hong Kong), Haroldo Lopez (Honduras), Angela H.E.M. Maas (Netherlands), Mpiko Ntsekhe (South Africa), Pat O'Donnell (Ireland), Gian Piero Perna (Italy), Miguel Quintana (Paraguay), Bagirath Raghuraman (India), Ruchit Shah (India), Vladimir Ullauri (Ecuador), Sarah Zaman (Australia), Jose Luis Zamorano (Spain), Yuhui Zhang (China), Sheng-hua Zhou (China), Shelley Zieroth (Canada), Rod Zimmermann (Canada), Habib Gamra[#] (Tunisia), Maria Ines Sosa Liprandi[#] (Argentina), Juan-Carlos Kaski[#] (UK)

**Drs. Caldeira, Gulati & Pinto would like to be considered joint first authors.*

[#]Drs. Gamra, Sosa Liprandi & Kaski would like to be considered joint senior authors.

Note: all authors were either writing task force members or active guideline reviewers. The author affiliations are listed at the end of the document.

Abstract

There are a number of guidelines on how to manage ischemic heart disease (IHD), but inconsistencies in healthcare access, varying infrastructure, resource constraints and diverse local practices restrict their global applicability. This underscores the need for universal recommendations that address the unique challenges faced by patients and healthcare providers worldwide. Our Global Guidelines emphasize the incorporation of novel therapies, while integrating standards of care with the most up-to-date evidence to enable clinicians to optimize IHD management. These Global Guidelines provide evidence-based recommendations that represent a group consensus considering the previously published guidelines that have reviewed many of the issues related to the management of IHD but have also provided recommendations on several issues where resource limitations may put constraints on the evaluation and treatments provided to patients with IHD. Such recommendations aim to guide situations when resources are somewhat limited or when resources are severely limited. Hence, this document presents a comprehensive update to IHD management guidelines, thereby aiming to provide a unified strategy for the management of IHD that is applicable to all cardiovascular care worldwide.

Key words: Guidelines, iCARDIO Alliance, Ischemic Heart Disease.

Received: 17 July 2025; Accepted: 21 July 2026.

**Correspondence to: Fausto J. Pinto, Faculdade de Medicina da Universidade de Lisboa, Centro Academico de Medicina de Lisboa, CCUL@RISE, Lisbon, Portugal.*

E-mail: faustopin@gmail.com

Preamble

The International CARDIO Alliance to Improve Disease Outcomes (iCARDIO Alliance: <https://icardioalliance.org>) aims to bring together leading cardiovascular societies around the globe as partner organizations to improve the quality of cardiovascular care, from prevention and diagnosis to treatment and follow-up. The goal of these global implementation guidelines is to achieve global representation on writing panels and to produce concise and practical guidelines applicable to all cardiovascular care worldwide.¹ In addition to clinical practice guidelines developed by other medical associations, the recommendations by iCARDIO Alliance take into account availability of resources, with specific recommendations for resources severely limited.

Concepts

Ischemic heart disease (IHD) remains the leading cause of morbidity and mortality worldwide. Coronary artery disease (CAD) encompasses any pathological process capable of compromising myocardial perfusion and although numerous etiologies exist, including vasculitis, spontaneous coronary artery dissection, and coronary embolism, the majority of CAD is attributable to coronary atherosclerosis, which constitutes the focus of this document. For practical purposes, CAD is considered present when any degree of atherosclerotic involvement exceeds zero percent stenosis, recognizing that even minimal coronary atherosclerosis represents a systemic disease process with prognostic implications.

Chronic ischemic heart disease (CIHD) represents the traditional designation for the stable manifestations of coronary atherosclerosis, emphasizing myocardial ischemia resulting from an imbalance between oxygen supply and demand. In 2019, the European Society of Cardiology introduced the concept of chronic coronary syndromes (CCS),² while the American Heart Association and American College of Cardiology, in their 2023 guidelines, adopted the term chronic coronary disease.³ Despite subtle semantic differences, these terms are largely synonymous, all referring to the chronic, stabilized phases of coronary atherosclerosis as distinct from acute coronary syndromes. Throughout this document, we have chosen to use the term CIHD.

While this document addresses CIHD, a critical question is, when the acute phase transitions to the *chronic* phase. The acute coronary syndromes are characterized by plaque rupture or erosion, acute thrombus formation, and dynamic coronary obstruction, with immediate priorities centered on urgent or emergent reperfusion. The transition to the chronic phase occurs when the acute thrombotic process has resolved and the patient enters a period of relative pathophysiological stability, by convention, at 12 months following an acute coronary syndrome, reflecting the observation that recurrent ischemic event rates plateau after approximately one year. However, the chronic phase is not synonymous with low risk, as

This is a consensus document with guidelines being written by a team including world-renowned experts with a maximum of 50% of the writing task force representing Europe and North America and 50% or more from the rest of the world. The guideline recommendations were adapted by reviewing different guidelines about the topic. The peer review team was made up of global experts further enriching these documents and leading to a final phase of the guidelines ready for a public review process, so that the viewpoints of persons with lived experience can be embedded within this global implementation guideline process. These comments were evaluated and addressed when relevant by the Review Coordinators. With this innovative approach iCARDIO Alliance hopes to enhance guideline dissemination and implementation on a global scale.

the atherosclerotic process continues and previously stable plaques may become vulnerable.

In CIHD, the focus shifts to adequate identification, risk stratification and long-term secondary prevention and, when indicated, coronary revascularization. Among the pillars of secondary prevention, antithrombotic therapy merits particular attention due to its complexity and evolving evidence base. Its selection, intensity, duration, and adaptations represent nuanced clinical decisions that are influenced by the balance between ischemic risk reduction and bleeding risks, specific co-morbidities, and time passed since the acute event, and sometimes occurs earlier than the conventional 12 months. This document addresses the assessment and management of patients with CIHD, including the diagnosis and risk stratification, pharmacological therapy, revascularization, specific clinical conditions, special populations, and long-term follow-up.

Grading/recommendations

Recommendations about benefits and harms were classified based on the consensus of the writing committee after reviewing guidelines and available evidence.

The categories of recommendations are intended to guide clinicians globally, with flexibility to apply recommendations according to local resources, clinical judgment, and patient needs.

Based on the available evidence and consensus among the committee members regarding the risks and benefits of interventions, the recommendations were classified as Strongly Recommend (SR), Recommend (R), Suggest (Su), and Do Not Do (DND) (Table 1).

Burden of ischemic heart disease

IHD remains the leading global cause of death and disability. It is responsible for approximately 9 million deaths annually and affects an estimated 126 million people worldwide, ac-

counting for about 1.72% of the global population.⁴⁻⁶ This translates to a prevalence rate of approximately 1655 cases per 100,000 people, with trends consistently showing IHD as the dominant non-communicable cause of mortality for over two decades.^{4,7,8}

IHD has also an important socioeconomic burden.⁹ It is associated with an increased risk of disability, and a 1.5-fold greater risk of unemployment.¹⁰ It is currently the leading contributor to disability-adjusted life years worldwide due to non-communicable diseases.^{6,8,11} By 2030, global prevalence is projected to exceed 1845 per 100,000, with forecasts suggesting a rise to 1917 per 100,000 in certain regions.⁵ This escalation is driven by the rising prevalence of cardiovascular risk factors,¹²⁻¹⁴ but also due to aging of populations.

The United Nations projected that the population over age 65 will increase from 1 in 11 in 2019 to 1 in 6 by 2050,¹⁵ substantially increasing the clinical and economic burden on health-care systems.

The financial impact of IHD is both direct and indirect. In high-income countries, healthcare expenditures for IHD approach 1-1.5% of Gross Domestic Product, while in low- and middle-income countries, up to 10% of health budgets are spent on cardiovascular disease care, with devastating consequences for household economics.^{9,16}

While IHD poses a significant global challenge, its burden varies widely by region. Eastern Europe bears a particularly heavy cardiovascular burden,¹⁷ where socioeconomic and healthcare limitations amplify lifestyle-related risk factors. In contrast, some regions in Asia and Africa are seeing evolving patterns marked by underdiagnosis, increasing exposure to risk factors and undertreatment, resulting in an emerging epidemic.^{16,18-20}

Also, in IHD, sex disparities remain evident, with men experiencing a higher IHD prevalence (1786 per 100,000) than women (1522 per 100,000), though postmenopausal incidence in women rises sharply.⁵

Beyond these epidemiological trends, the burden of CIHD represents a particularly pressing challenge for healthcare systems. This burden arises from two main sources: the growing population of patients who survive after an Acute Coronary Syndrome (ACS) event and subsequently transition into CCS stage; and second, those who present *de novo* with CCS without preceding ACS.

Assessment of ischemic heart disease

The assessment of suspected CIHD or CCS involves a comprehensive evaluation of clinical features, biomarkers, electrocardiogram, imaging and invasive approach in selected cases. Proper evaluation allows risk stratification, and directs further investigations, to improve symptoms, quality of life and cardiovascular outcomes.^{3,21}

Clinical presentation

The typical symptom of CIHD is chest pain, but only 10% to

25% of patients undergoing functional or anatomical testing in contemporary cohorts, experience classic angina.^{22,23} Most individuals present with nonspecific symptoms, such as chest discomfort rather than pain, throat, arm, jaw discomfort, nausea, exertional dyspnea, diaphoresis or fatigue. Classic angina is defined as substernal pressure triggered by exertion or emotional stress that improves with rest or nitroglycerin.

Women frequently report non-classical symptoms such as jaw pain, epigastric discomfort, nausea, or unexplained fatigue — leading to under recognition and delayed diagnosis.²⁴ Risk scores (such as SCORE2, Pooled Cohort Equation, PREVENT) often underestimate cardiovascular risk in women. In older people, IHD may present with non-anginal symptoms, including syncope, delirium, or breathlessness (Table 2).

Biomarkers

High-sensitivity cardiac troponin assays allow rapid exclusion or confirmation of myocardial injury and should be used to evaluate patients with suspected ACS. Creatine Kinase MB fraction may be useful in the suspicion of recurrent myocardial infarction in patients with recent myocardial infarction. This includes post-procedural (percutaneous coronary intervention or coronary artery bypass graft surgery) myocardial infarction.²⁵ Myoglobin is no longer recommended for diagnostic purposes.

Reversible causes of ischemia such as anemia and hyperthyroidism should be evaluated. Lipid profile, creatinine, microalbuminuria and glycemic indices (fasting glucose and HbA1c) should also be part of the routine blood workup in suspected IHD. Lipoprotein(a), which should be checked in adults once in a lifetime, is currently a marker that may help to identify patients at high risk of early-onset or severe atherosclerosis.²⁶ Markers of inflammation, such as high-sensitivity C-reactive protein, are associated with worse prognosis and may guide intensification of lipid-lowering therapy or consideration of anti-inflammatory treatment. Natriuretic peptides are useful for prognosis in patients with IHD and well as those with suspected heart failure (Table 3).

Rest and exercise electrocardiogram

A resting 12-lead electrocardiogram (ECG) is fundamental in the evaluation of IHD and should be performed promptly within the first 10 minutes after the first medical contact in all patients with acute chest pain.²⁷ ST-segment elevation or depression, Q waves, conduction abnormalities or complex ventricular arrhythmias may indicate ongoing ischemia or previous myocardial infarction. In patients with persistent symptoms and a nondiagnostic ECG, serial ECGs and/or posterior leads (V7-V9), and/or right precordial leads may improve diagnostic yield when posterior myocardial infarction is suspected.²⁸ Exercise ECG is less sensitive and less specific for diagnosis but remains valuable for evaluating functional capacity and stratifying event risk.²⁹ Its accuracy is reduced with baseline ECG abnormalities or concurrent use of digitalis (ST-T abnormalities or left bundle branch block) (Table 4).

Non-invasive cardiac imaging

Both anatomic and functional imaging play a fundamental role in the diagnosis of IHD. Coronary computed tomography angiography (CCTA) identifies coronary stenoses and atherosclerotic plaque and is recommended for evaluating patients at low to intermediate risk. The SCOT-HEART trial confirmed the prognostic value of CCTA in CIHD,³⁰ which can be complemented by non-invasive fractional flow reserve (FFR) evaluated by CCTA further to assess the hemodynamic significance of intermediate stenoses.

Stress imaging [*e.g.*, echocardiography, positron emission tomography (PET)/single-photon emission computed tomography (SPECT), Cardiovascular magnetic resonance (CMR)] provides key data on myocardial perfusion, wall motion, and ischemia burden. All can be useful to detecting ischemia with non-obstructed coronary arteries (INOCA), but does not define the underlying endotype (*e.g.*, microvascular vs vasospastic), when obstructive CAD has been ruled out. Test choice should consider availability, local expertise, pre-test probability, and patient characteristics (Table 5).

Invasive assessment of chronic ischemic heart disease

In IHD, invasive coronary angiography (ICA) is still the gold standard for coronary anatomy evaluation and may be preferable in:

- 1) Very high pre-test probability of obstructive CAD;
- 2) High-risk patients with findings of poor prognosis:
 - Severe left ventricular dysfunction
 - Low-threshold angina or equivalent / Duke Treadmill score < -10,
 - Complex ventricular arrhythmia
- 3) High-risk patients after imaging testing
 - significant ischemia in imaging methods
 1. ≥ 3 of 16 segments with stress-induced hypokinesia or akinesia in stress echocardiography
 2. area of ischemia $\geq 10\%$ of the LV myocardium in stress SPECT or PET
 3. ≥ 2 of 16 segments with stress perfusion defects or ≥ 3 dobutamine-induced dysfunctional segments in stress CMR
 - CT showing left main disease with $\geq 50\%$ stenosis, three-vessel disease with $\geq 70\%$ stenosis, or two-vessel disease including the proximal left anterior descending artery (LAD) with $\geq 70\%$ stenosis, or one-vessel disease of the proximal LAD with $\geq 70\%$ stenosis and FFR-CT ≤ 0.8 .
- 4) Persistent symptoms related to IHD despite optimal medical treatment
- 5) Patients with inconclusive yet suspicious non-invasive tests.

In CIHD context, physiological lesion assessment using FFR or instantaneous wave-free ratio (iFR) helps in the guidance of revascularization decisions and may lead to outcomes improvement.^{31,32}

In symptomatic patients with IHD and non-obstructive coronary arteries, ANOCA/INOCA should be considered, and — where available — coronary functional tests (*e.g.*, coronary flow reserve, index of microvascular resistance, acetylcholine provocation) performed by experienced operators are essential to identify microvascular and/or vasospastic mechanisms (Table 6).

Treatment of chronic ischemic heart disease

The management of CIHD relies upon multifaceted modification of risk factors, pharmacotherapy, and revascularization where indicated. A stepwise evidence-based approach is critical to maximize prognosis, manage symptoms, and avoid disease progression.

Lifestyle modification and preventive strategies

In addition to disease modifying medication, lifestyle interventions included in cardiac rehabilitation programs are the cornerstone of IHD care. These programs include organized regimens of diet, physical activity, smoking cessation programs, and psychosocial support (to address depression, stress, social isolation...) which reduce cardiovascular events and improve quality of life.

Diets rich in vegetables, fruits, legumes, nuts, whole grains, and lean protein, such as the Mediterranean diet (which also includes fish and olive oil), has been shown to provide consistent cardiovascular benefit.^{33,34} Low sodium intake was associated with lower risk of events in patients with CIHD,³⁵ particularly those with hypertension.³⁶ Physical activity of 150-300 minutes/week at moderate intensity or 75-150 minutes/week at vigorous intensity is associated with a substantial reduction in mortality. Smoking cessation reduces the risk of premature death by over one-third. Alcohol consumption should be stopped or restricted to maximally recommended thresholds for males and females.

Behavioral interventions, included in cardiac rehabilitation programs, are critical to sustaining lifestyle change. Mobile health tools and structured education may improve adherence and outcomes. Influenza vaccination should be recommended to all patients with IHD³⁷⁻³⁹ (Table 7 and Figure 1).

Risk factor management

Diabetes mellitus

Patients with IHD and type 2 diabetes mellitus are at elevated risk for recurrent cardiovascular events. Treatment should include agents with demonstrated cardiovascular benefit, particularly sodium-glucose cotransporter-2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists alongside glycemic control.⁴⁰⁻⁴² SGLT2 inhibitors and GLP-1 receptor agonists reduce the risk of cardiovascular events, hospitalizations with heart failure, and progression of renal dysfunction, independent of glycemic targets.⁴³

Lipid management

A low-density lipoprotein cholesterol (LDL-C) goal <1.4 mmol/L (55 mg/dL) and at least a 50% reduction from baseline are recommended in patients with established IHD. High-intensity statin therapy is the first-line treatment, with or without ezetimibe, where available and accessible.^{44,45} The addition of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors should be considered if targets are unmet,^{46,47} based on further risk reduction with these drugs. Bempedoic acid can also be considered in this context. Follow-up after initiation or change in treatment should at least after 1 month to assess the goal achievement (and tolerability). Icosapent ethyl (2 grams twice daily) may be used in patients with IHD and hypertriglyceridemia (>150 mg/dL).⁴⁸ For statin-intolerant patients bempedoic acid (preferably with ezetimibe to achieve LDL-C goal) should be considered.⁴⁹

Hypertension

Blood pressure targets are generally set at $<130/80$ mmHg for most patients with IHD. First-line agents include Angiotensin Converting Enzyme Inhibitors (ACE-I) or angiotensin receptor blockers, often combined with dihydropyridine calcium channel blockers or thiazide/thiazide-like diuretics in single-pill combination should be preferred to improve adherence. Beta-blockers can be important in patients with prior myocardial infarction with incomplete revascularization or in those with heart failure with reduced ejection fraction.

Inflammation

Inflammation plays a central role in atherogenesis and cardiovascular events. Targeting residual inflammatory risk, several clinical trials have explored therapies that reduce inflammatory activity independent of lipid-lowering. Canakinumab, a monoclonal antibody against interleukin-1 β , demonstrated reduced cardiovascular events in the CANTOS trial but has not been commercialized for this indication.⁵⁰ Low-dose colchicine reduced cardiovascular events in trials such as COLCOT and LoDoCo2,^{51,52} making it a feasible anti-inflammatory option in secondary prevention, despite the absence of benefits in the CLEAR trial post-MI (Table 8 and Figure 2).⁵³

Antianginal and antithrombotic therapy

The primary goals of pharmacologic therapy in IHD are symptom improvement, improvement of quality of life, and prevention of adverse cardiovascular events.

Antianginal therapy

The conventional approach to antianginal therapy has followed a hierarchical, stepwise model using first-line agents

(beta-blockers, calcium channel blockers) and second-line drugs (long-acting nitrates, nicorandil, ranolazine, ivabradine, trimetazidine). This hierarchical approach does not reflect the differences of efficacy of the antianginal drugs in cardiovascular outcomes. Therefore, medical therapy with antianginal drugs in CIHD should be individualized based on patient-specific factors, and flexibilized according to aspects such as the hemodynamic profile (blood pressure, heart rate), comorbidities (notably heart failure or atrial fibrillation), concomitant medications (considering drug interactions; for example ranolazine prolongs modestly the QT interval and caution is warranted when used with other QT-prolonging drugs, despite the safety and efficacy of ranolazine in the arrhythmic profile), patient preferences and the underlying pathophysiology of ischemia.⁵⁴ In fact, different endotypes of ischemia require different treatments. Local drug availability should also be considered. The use of fixed-dose combinations is encouraged to improve adherence and clinical outcomes (Table 9).

Antithrombotic therapy

Antiplatelet therapy with low-dose aspirin (75–100 mg daily) or clopidogrel (75 mg) is recommended for all IHD patients without an indication for oral anticoagulation or for dual antiplatelet therapy (DAPT).⁵⁵

Standard DAPT regimens with aspirin and a P2Y₁₂ inhibitor (ticagrelor, prasugrel, or clopidogrel) should be given for 12 months after myocardial infarction, but can be shorter or longer, depending on bleeding vs. ischemic risk. In CIHD the recommended DAPT duration is 1–3 months for high bleeding risk, 6 months for standard risk, and ≥ 12 months for high ischemic risk.^{21,56} Extended DAPT beyond 12 months using aspirin with clopidogrel, ticagrelor, or adding rivaroxaban (2.5 mg twice daily) to aspirin should be considered in high ischemic risk patients without elevated bleeding risk.

De-escalation therapies should be considered in patients at high bleeding and low ischemic risk. These include switching from ticagrelor or prasugrel to clopidogrel, also the reduction of prasugrel from 10 mg to 5 mg, or ticagrelor 90 mg twice daily after 1–3 months and continuation for 12–15 months as monotherapy without aspirin (Table 10 and Figure 3).

Revascularization: percutaneous coronary intervention and coronary artery bypass graft surgery

Revascularization may be required for symptom relief, for prognostic improvement, or both. The decision between medical therapy alone, percutaneous coronary intervention (PCI), or CABG should be based on symptom burden, ischemia burden and/or anatomical complexity of coronary lesions, as well as individual risk factors such as frailty or patients' preferences.

PCI is preferred in single- or two-vessel disease without diabetes. In contrast, CABG provides better outcomes in pa-

tients with diabetes, multivessel disease, and/or high SYNTAX scores.⁵⁷⁻⁵⁹ CABG has also shown long-term improvement of survival compared to optimal medical therapy in patients with multivessel disease and Left Ventricular Ejection Fraction (LVEF) $\leq 35\%$.⁵⁸

Functional lesion assessment using FFR or iFR along with intravascular imaging are useful in the selection of lesion and PCI optimization.⁶⁰⁻⁶²

A Heart Team approach is recommended for complex cases. SYNTAX score II (preferably SYNTAX score II 2020) may be considered as an adjunct to integrate clinical and anatomic factors, facilitate individualized risk communication, and support shared decision-making (Table 11).

Specific clinical conditions in ischemic heart disease

Heart failure and chronic ischemic heart disease

Heart failure (HF) resulting from IHD is a leading cause of morbidity and mortality, responsible for approximately 50% of all HF cases in industrialized countries. Contributing mechanisms include prior myocardial infarction resulting in loss of viable tissue, as well as chronic ischemia leading to hibernating myocardium.

Echocardiographic classification based on LVEF distinguishes HF with reduced EF (HFrEF $< 50\%$) and HF with preserved EF (HFpEF $\geq 50\%$). (see also updated 2026 Global Guidelines on Heart Failure.)

Clinical evaluation includes assessment of symptoms, measurement of biomarkers (*e.g.*, natriuretic peptides), imaging including echocardiography and may include other modalities such as PET/SPECT, CMR, coronary CTA, or invasive coronary angiography. Further guidance on heart failure management is available in disease-specific guidelines (Table 12).^{63,64}

Microvascular angina, vasospastic angina, and ischemia with non-obstructive coronary arteries

Ischemia with Non-Obstructive Coronary Arteries (INOCA) includes microvascular angina and vasospastic angina. These syndromes are more prevalent in women, associated with significant symptoms and an unfavorable prognosis.^{65,66}

Pathophysiology involves coronary microvascular dysfunction and/or epicardial coronary artery spasm. Diagnosis requires invasive coronary functional testing or non-invasive stress imaging with coronary flow reserve assessment, which can be assessed using stress CMR, PET and stress echo (Table 13).

Refractory angina

Refractory angina is characterized by persistent chest pain lasting longer than three months, caused by myocardial ischemia that does not respond adequately to optimal medical

therapy or revascularization. It may result from obstructive coronary artery disease or INOCA. Emerging treatment strategies from small trials and/or registries include enhanced external counterpulsation (EECP), coronary sinus reducer devices, spinal cord stimulation and extracorporeal cardiac shock wave therapy (CSWT),⁶⁷⁻⁷³ available in limited specialized centers (Table 14).

Other specific conditions

Atrial fibrillation

AF frequently coexists with coronary disease, complicating symptom interpretation and increasing thromboembolic risk. Coronary artery stenosis exceeding 50% luminal obstruction attributes 1 point to the CHAD2S2-VA score and adds to the thromboembolic risk. Rate or rhythm control strategies should be individualized based on LVEF, symptoms, and comorbidities. Anticoagulation is essential for stroke prevention, and single antiplatelet therapy should be discontinued if anticoagulation is initiated.⁷⁴

Chronic kidney disease

Chronic kidney disease (CKD) patients are at high risk of both ischemic and bleeding events. PCI should not be withheld solely due to contrast-induced nephropathy risk. Hydration and procedural planning are important to minimize nephrotoxicity. The volume of contrast material should be minimized in ICA for diagnosis or intervention purposes. The risks associated with an early invasive strategy were highlighted in the ISCHEMIA-CKD study. Patients with advanced kidney disease and moderate or severe ischemia on stress testing, undergoing early invasive strategy, showed an increased risk of stroke and death or initiation of dialysis, without improving the risk of death or myocardial infarction.⁷⁵

Cancer

Cancer therapies may increase cardiovascular risk. A multidisciplinary cardio-oncology approach is essential to balance cancer treatment with IHD management, particularly in cases of cardiotoxicity or thrombotic risk.⁷⁶

HIV

Individuals living with HIV have an increased risk of cardiovascular disease, partially due to antiretroviral therapy impact on lipid profiles. When prescribing statins, clinicians should choose agents with minimal drug interactions, acknowledging that protease inhibitors have strong interference with cytochromes, *i.e.* CYP3A4. Simvastatin and lovastatin are contraindicated in this setting. Pitavastatin showed favorable results in the primary prevention setting,⁷⁷ but atorvastatin or rosuvastatin may be used at the maximum dose allowed and tolerated by the protease inhibitors regimen, along with eze-

timibe and/or PCSK9 inhibitors if required to achieve and maximize LDL-C goals. When relevant, icosapent ethyl may have a role in the prognosis improvement with residual hypertriglyceridemia. When antiplatelet therapy with P2Y12 inhibitors is required, prasugrel, differently from clopidogrel and ticagrelor, does not have relevant interactions with protease inhibitors.

High Bleeding Risk

Validated bleeding risk scores (*e.g.*, PRECISE-DAPT, ARC-HBR) should guide antithrombotic therapy. In high-risk patients, DAPT duration may need to be shortened. A proton pump inhibitor (PPI) should be considered to reduce gastrointestinal bleeding risk (Table 15).

Special considerations in chronic ischemic heart disease

Certain populations require individualized assessment and therapy in the management of CIHD. Women and older/frail adults often have diagnostic delays, suboptimal treatment patterns, and increased procedural risks. This section provides guidance to optimize care in these groups.

Women: addressing under recognition, delayed diagnosis and undertreatment

Despite significant advancements in cardiovascular medicine, women with CIHD continue to be underdiagnosed and undertreated. Cardiovascular disease remains the leading cause of death among women worldwide, yet gender-based disparities persist in both diagnosis and treatment of the disease.⁷⁸ These gaps arise not only from biological differences but also from systematic biases in clinical evaluation.

The clinical presentation of CIHD in women more frequently diverges from the classical pattern of exertional chest pressure seen in men. Women commonly report breathlessness, fatigue, epigastric discomfort, or pain radiating to the neck or jaw.^{21,79-81} Emotional stress, more than physical exertion, is a frequent trigger. The symptoms experienced by women are often misattributed to anxiety, gastrointestinal disorders, or musculoskeletal pain, leading to diagnostic delays and late initiation of treatment. The more frequent absence of obstructive CAD must not be mistaken for the absence of CIHD.

Treatment disparities include lower use of evidence-based medications such as antiplatelets, statins, beta-blockers, and ACE-I.⁸² Women are also less likely to be referred to cardiac rehabilitation programs. Differences in body composition and drug metabolism may further impact treatment effectiveness and side effect profiles.

Addressing these disparities requires a tailored, sex-specific approach. Comprehensive symptom assessment should routinely include non-classic features. When non-obstructive findings are present, functional testing may help uncover mi-

crovascular disease. Personalized risk assessment must integrate female-specific risk factors to optimize outcomes and close the care gap, such as history of hypertensive disorders of pregnancy (preeclampsia/eclampsia), gestational diabetes, premature menopause, in addition to consideration of female predominant conditions, like autoimmune diseases (Table 16).⁸³

Older people and frail patients

The ongoing demographic shift toward an aging population has significantly influenced cardiovascular care. Adults aged 75 and older now represent the most rapidly expanding group among those living with chronic coronary syndromes. Managing ischemic heart disease (IHD) in this population presents unique challenges due to a higher burden of comorbidities, diminished physiological reserves, and increased vulnerability to risks associated with both diagnostic evaluations and therapeutic procedures. Frailty—marked by reduced strength, endurance, and physiological function—commonly coexists with cardiovascular disease and affects over 25% of patients with established IHD.^{84,85}

Older adults often present with non-classic or atypical manifestations of myocardial ischemia. Rather than typical angina, symptoms may include dyspnea, fatigue, confusion, delirium, or functional decline. Silent ischemia is also more prevalent, particularly in individuals with diabetes or prior infarction. Cognitive impairment may limit symptom reporting and affect adherence, further complicating assessment.

A key principle in managing older patients is individualized care, guided by life expectancy, comorbidities, procedural risk, and patient preferences. Frailty assessment tools and comprehensive geriatric assessment (CGA) can inform decision-making, particularly regarding revascularization. CGA evaluates medical, functional, cognitive, psychological (depression and dementia), nutritional, and social domains, and has been shown to improve prognostication and care planning.

Despite these complexities, older adults with IHD can benefit from medical therapy and revascularization—provided risks are carefully weighed and management aligns with patient-centered goals.

Older people have increased bleeding risk, especially during dual antiplatelet therapy (DAPT). Shorter DAPT durations (1-3 months) may be preferred when ischemic risk is low and bleeding risk is high. Clopidogrel might be chosen over more potent agents in these circumstances.^{21,56}

Use of PPIs is recommended during DAPT to reduce gastrointestinal bleeding (Table 17).

Follow-up of patients with chronic ischemic heart disease

Long-term follow-up plays a crucial role in the management of patients with CIHD, supporting sustained risk reduction,

treatment adherence, and the early detection of clinical deterioration. A structured, personalized approach to follow-up enhances clinical outcomes, promotes quality of life, and helps optimize healthcare resource utilization.

The primary goals of follow-up in patients with CIHD are:

- Evaluate new symptoms onset, or symptoms progression.
- Detect complications or recurrence of ischemic events.
- Ensure adherence to pharmacologic therapy and lifestyle modifications.
- Reinforce secondary prevention, including cardiovascular risk factor control.

Maintaining all treatment goals, particularly the use of antiplatelet drugs, smoking cessation, recommended LDL-C and blood pressure levels, is associated with better outcomes.⁸⁶

Follow-up should begin soon after the index event or diagnosis, typically within 6–8 weeks and continue at intervals tailored to the patient's clinical stability and overall risk profile. Those who have recently undergone revascularization, experience ongoing symptoms, or present with complex comorbidities may require more frequent and intensive monitoring.

Each follow-up visit should include a detailed clinical history and physical examination, complemented by review of medications, symptom status, lifestyle adherence, and psychological well-being. Serial ECGs and biomarker assessments may be indicated in specific contexts. Further diagnostic testing is warranted when symptoms change, or with clinical suspicion of disease progression or new ischemia.

A multidisciplinary approach involving primary care, cardiology, rehabilitation, and allied health professionals improves continuity and outcomes. Communication between care levels is essential for managing transitions post-discharge and for tailoring care to the patient's context.

The use of electronic health records, structured care plans, and patient education tools enhances patient engagement, particularly in those with polypharmacy. Shared decision making

should be utilized to improve treatment adherence and patient empowerment.

Cardiac rehabilitation should be strongly encouraged, as it improves exercise tolerance, medication adherence, psychosocial health, and survival. Despite these benefits, referral rates remain suboptimal, particularly among women, minorities, and older people.

Patients should be periodically reassessed for ongoing needs for antianginal therapy, intensity of antithrombotic therapy, and possible de-escalation of pharmacologic regimens in light of evolving risk-benefit considerations.

Conclusions

These global guidelines from the iCardio Alliance provide comprehensive, resource adaptive recommendations for the assessment, diagnosis, treatment, and follow up of CIHD. These guidelines are a consensus document that emphasize equity and patient-centered care across diverse healthcare settings. Application of guideline directed care globally has the potential to improve the outcomes of those living with this form of cardiovascular disease. Despite this aim, it is important to recognize that several areas warrant prioritization in future CIHD research. Current evidence derives disproportionately from trials conducted in high-income countries, with underrepresentation of women, older adults, and ethnically diverse populations; future studies must address this imbalance to ensure generalizability, as shown in a recent survey.⁸⁷ Implementation science, examining how guidelines are adopted and sustained across diverse health systems, should equally be regarded as a research priority in its own right.

Therefore, as science is evolving, the iCardio Alliance is committed to their regular review and to fostering the collaborative global networks, with clinicians, researchers, patients, and policymakers, necessary to ensure that advances in CIHD care translate into meaningful and equitable reductions in its global burden.

Table 1. Grading and recommendation

No.	Guideline statement	Level of Recommendation
1-01	Evidence or consensus that a specific diagnostic test or treatment is effective, beneficial and valuable.	Strongly Recommend (SR)
1-02	Majority of evidence or opinions support the benefits or effectiveness.	Recommend (R)
1-03	Usefulness or effectiveness is less clearly supported by evidence or opinion.	Suggest (Su)
1-04	Evidence or consensus suggests that it is ineffective and, in some cases, may even be harmful.	Do not do (DND)

Table 2. Initial clinical assessment recommendations.

No.	Guideline statement	Level of Recommendation
2-01	Assess the cardiovascular risk factors, medical history, and symptom characteristics in all individuals with symptoms of suspected myocardial ischemic origin.	SR
2-02	Assess the characteristics, duration, and associated features in all patients with chest pain or chest discomfort.	SR
2-03	Consider IHD in women who present with chest pain or other symptoms such as jaw pain, epigastric discomfort, nausea, or unexplained fatigue.	SR
2-04	Consider ACS in older people with acute dyspnea, syncope or acute delirium.	SR

ACS, acute coronary syndrome; IHD, ischemic heart disease; SR, strong recommendation.

Table 3. Biomarker recommendations.

No.	Guideline statement	Level of Recommendation
3-01	Request in all individuals with suspected IHD: full blood count including hemoglobin; creatinine with estimated GFR, microalbuminuria, lipid profile including LDL-C, and glycemic status with HbA1c and/or fasting plasma glucose.	SR
3-02	Request thyroid function in patients with suspected CIHD.	SR
3-03	Lipoprotein(a) should be evaluated (at least once) in patients with suspected CIHD.	R

To be continued on next page

3-04	High-sensitivity C-reactive protein may be considered to further stratify the risk in those with CIHD.	Su
3-05	Measure the troponin in all patients with suspected ACS, and repeat if the first value is non-diagnostic.	SR

ACS, acute coronary syndrome; CIHD, chronic ischemic heart disease; HbA1c, hemoglobin A1c; GFR, glomerular filtration rate; LDL-C, low-density lipoprotein cholesterol; R, recommendation; SR, strong recommendation; Su, suggestion.

Table 4. Electrocardiogram and exercise electrocardiogram recommendations.

No.	Guideline statement	Level of Recommendation
4-01	Perform a 12-lead ECG in all individuals with suspected IHD.	SR
4-02	In patients with acute chest pain, a resting 12-lead ECG should be acquired and reviewed for STEMI within 10 minutes after first medical contact.	SR
4-03	In patients with chest pain and a nondiagnostic initial ECG, serial 12-lead ECGs should be performed when clinical suspicion of ACS is high, symptoms are persistent, or the clinical condition deteriorates.	SR
4-04	Consider exercise ECG in selected patients without chest pain and no ACS, to assess exercise tolerance, symptoms, arrhythmias, blood pressure response, and event risk, when the information is likely to change the diagnostic or treatment plan.	R
4-05	Do not order an exercise ECG to rule out obstructive CAD in patients in whom ACS is suspected.	DND
4-06	Do not order an exercise ECG as preferred test to rule out obstructive CAD in low-intermediate risk patients when CCTA or functional imaging tests are available and accessible	DND
4-07	Exercise ECG is not recommended for diagnostic purposes in patients with ≥ 0.1 mV ST-segment depression on resting ECG, left bundle branch block, ventricular pacing or who are being treated with digitalis.	DND
<i>Resources severely limited</i>	<i>Use exercise ECG as a risk stratification exam if CCTA or functional imaging tests are unavailable.</i>	
<i>Resources severely limited</i>	<i>In patients at intermediate or high pre-test probability for CAD, optimal medical therapy should be provided to address modifiable risk factors, if functional or anatomic imaging tests are not available or where financial resources are restricted.</i>	

CAD, coronary artery disease; CCTA, coronary computed tomography angiography; DND, do not do; ECG, electrocardiogram; R, recommendation; SR, strong recommendation; STEMI, ST-elevation myocardial infarction.

Table 5. Non-invasive imaging recommendations.

No.	Guideline statement	Level of Recommendation
5-01	Order a transthoracic echocardiogram to assess LVEF, identify regional wall motion abnormalities, detect non-coronary cardiac disease, and refine risk stratification.	SR
5-02	Request chest radiography in patients with chest pain to evaluate for other potential cardiac, pulmonary, and thoracic causes of symptoms. or to rule out pulmonary causes of chest pain.	SR
5-03	For low and intermediate risk patients with stable chest pain and no known CAD, CCTA (including FFR) is effective for diagnosis, risk stratification, and guiding treatment decisions.	SR
5-04	For intermediate and high risk patients with stable chest pain and no known CAD, stress imaging (echocardiography, PET/SPECT MPI, or CMR) is effective for diagnosis of myocardial ischemia and risk assessment.	SR
5-05	Perform functional imaging exam to assess myocardial ischemia if CCTA has shown CAD of uncertain functional significance or when it is not diagnostic.	SR

CAD, coronary artery disease; CCTA, coronary computed tomography angiography; CMR, cardiac magnetic resonance; FFR, fractional flow reserve; LVEF, left ventricular ejection fraction; PET, positron emission tomography; SPECT MPI, single photon emission computed tomography myocardial perfusion imaging; SR, strong recommendation.

Table 6. Invasive assessment recommendations.

No.	Guideline statement	Level of Recommendation
6-01	Perform invasive coronary angiography with physiological lesion assessment to confirm or exclude the diagnosis of obstructive CAD in individuals with high pre-test probability, severe or unstable symptoms uncontrolled by pharmacologic therapy, or high event risk based on clinical evaluation.	SR
6-02	Perform invasive coronary function testing in selected symptomatic patients with documented or suspected ANOCA/INOCA.	Su
<i>Resources severely limited</i>	<i>Invasive coronary angiography is indicated for high-risk or refractory patients in centers equipped with a cardiac catheterization laboratory. In the absence of required infrastructure, refer the patients to an equipped center.</i>	

ANOCA, angina with no obstructive coronary artery disease; CAD, coronary artery disease; INOCA, ischemia with no obstructive coronary artery disease; R, recommendation; SR, strong recommendation; Su, suggestion.

Table 7. Lifestyle recommendations.

No.	Guideline statement	Level of Recommendation
7-01	Refer all patients with IHD to a multidisciplinary exercise-based cardiac rehabilitation program to improve cardiovascular risk profile and reduce cardiovascular mortality.	SR
7-02	Aerobic physical activity of at least 150-300 min per week of moderate intensity or 75-150 min per week of high intensity and reduction in sedentary time.	SR
7-03	Following a diet emphasizing vegetables, fruits, legumes, nuts, whole grains, and lean protein (<i>e.g.</i> Mediterranean diet; and low sodium intake).	SR
7-04	Maintaining and achieving healthy weight (BMI 18.5-24.9 kg/m ² ; for Asians 18.5-22.9 kg/m ²) and target appropriate waist circumference (<94 cm for men, <80 cm for women, for Asian men <90 cm and <80 cm for Asian women).	SR
7-05	Smoking cessation is recommended for all smokers with referral to specialized services.	SR
7-06	Psychosocial assessment to direct psychological interventions is recommended.	SR
7-07	Influenza vaccination is recommended to all IHD patients.	SR
<i>Resources severely limited</i>	<i>Refer patients with IHD to structured follow-up programs to assess the adherence to all measures that improve cardiovascular risk profile.</i>	
<i>Resources severely limited</i>	<i>Encourage and reinforce at every visit, active lifestyle, healthy nutrition, and smoking cessation (when applicable) through brief physician advice and basic counseling.</i>	

BMI, body mass index; IHD, ischemic heart disease; SR, strong recommendation.

Table 8. Risk factor management recommendations.

No.	Guideline statement	Level of Recommendation
8-01	Use SGLT2 inhibitors with proven CV benefits in patients with CIHD associated with T2DM or HF to reduce CV events.	SR
8-02	Use GLP-1 receptor agonists with proven CV benefit in obese patients with T2DM and CIHD to reduce CV events.	SR
8-03	Consider semaglutide in CIHD patients without T2DM with BMI ≥ 27 kg/m ² .	R
8-04	Prescribe lipid-lowering treatment in CIHD patients, with LDL-C goal of <1.4 mmol/L (55 mg/dL) and a $\geq 50\%$ reduction.	SR
<i>Resources severely limited</i>	<i>Prescribe the most potent and affordable available statin, at the maximally tolerated dosage.</i>	
8-05	Use a high-intensity lipid lowering treatment with high-intensity statin with or without ezetimibe in all patients with CIHD.	SR
8-06	Prescribe bempedoic acid preferably with ezetimibe in all patients with CIHD intolerant to statins.	SR
8-07	Prescribe PCSK9 inhibitor in patients who do not achieve their goal on a maximum tolerated dose of statin and ezetimibe, combination.	SR
8-08	Prescribe bempedoic acid in patients who do not achieve their goal on a maximum tolerated dose of statin and ezetimibe, combination.	Su
8-09	Consider icosapent ethyl (2 grams twice daily) is recommended in patients with CIHD and hypertriglyceridemia.	R
8-10	Prescribe ACE-I (or ARB) in patients with CIHD, with concomitant elevated blood pressure, diabetes, or heart failure.	SR
8-11	Consider low-dose colchicine in patients with CIHD	Su

ACE-I, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; BMI, body mass index; CIHD, chronic ischemic heart disease; CV, cardiovascular; GLP-1, glucagon-like peptide-1; HbA1c, hemoglobin A1c; HF, heart failure; IHD, ischemic heart disease; LDL-C, low-density lipoprotein cholesterol; PCSK9, proprotein convertase subtilisin/kexin type 9; R, recommendation; SGLT2, sodium-glucose cotransporter-2; SR, strong recommendation; Su, suggestion; T2DM, type 2 diabetes mellitus.

Table 9. Antianginal therapy recommendations.

No.	Guideline statement	Level of Recommendation
9-01	Prescribe short-acting nitrates for immediate relief of angina.	SR
9-02	Prescribe beta-blockers, CCBs, long-acting nitrates, nicorandil, ivabradine or metabolic agents, such as ranolazine or trimetazidine to control anginal symptoms of CIHD, when clinically appropriate.	SR
9-03	Prescribe antianginal drugs in monotherapy or as early-combination based on symptom burden and phenotype, and adjust according to the response.	R
9-04	Do not prescribe concomitantly verapamil or diltiazem with ivabradine in patients with CIHD.	DND

CCB, calcium channel blockers; CIHD, chronic ischemic heart disease; DND, do not do; R, recommendation; SR, strong recommendation.

Table 10. Antithrombotic therapy recommendations.

No.	Guideline statement	Level of Recommendation
10-01	Prescribe a single antiplatelet agent (low-dose aspirin or clopidogrel) in CIHD patients, unless on therapeutic anticoagulation for another indication or need for DAPT.	SR
<i>Resources severely limited</i>	<i>Prescribe low-dose aspirin to all CIHD patients, unless on therapeutic anticoagulation for another indication.</i>	
10-02	Prescribe rivaroxaban (2.5 mg twice daily) in addition to low-dose aspirin in selected stable high-risk CIHD patients (in patients who had ACS, consider this >1 year after ACS).	R
10-03	Prescribe low-dose aspirin and clopidogrel for 6 months as the default antithrombotic strategy after PCI-stenting in CCS patients without indication for oral anticoagulation (<i>e.g.</i> atrial fibrillation).	SR
10-04	Discontinue DAPT in 1-3 months after PCI, and continue single antiplatelet therapy in CCS patients at high bleeding risk, but not at high ischemic risk.	SR
Post ACS patients (12 months after ACS)		
10-05	Prescribe low-dose aspirin or clopidogrel (single antiplatelet therapy) as the default strategy after 12 months of the ACS event.	SR
10-06	Discontinue antiplatelet therapy and maintain oral anticoagulation in patients with indication for oral anticoagulation (<i>e.g.</i> atrial fibrillation).	SR

To be continued on next page

10-07	Prescribe dual antithrombotic therapy in patients with high ischemic risk and without high bleeding risk: a) Low-dose aspirin and clopidogrel 75 mg. b) Low-dose aspirin and prasugrel 10 mg (or 5 mg if increased ≥ 75 years or body weight < 60 Kg). c) Low-dose aspirin and ticagrelor 60 mg twice daily. d) Low-dose aspirin and rivaroxaban 2.5 mg twice daily.	R
10-08	Prescribe ticagrelor 90 mg twice daily (single antiplatelet therapy) after 12 months of the ACS event in patients with high ischemic risk and without high bleeding risk.	Su
10-09	Do not use prasugrel in patients with prior stroke.	DND

ACS, acute coronary syndrome; CCS, chronic coronary syndrome; CRT, cardiac resynchronization therapy; DAPT, dual antiplatelet therapy; DND, do not do; PCI, percutaneous coronary intervention; R, recommendation; SR, strong recommendation; Su, suggestion.

Table 11. Revascularization recommendations.

No.	Guideline statement	Level of Recommendation
11-01	Perform myocardial revascularization of functionally significant lesions to improve symptoms and/or prognosis in CIHD patients with persistent angina or anginal equivalents, despite optimal medical treatment, or significant ischemia.	SR
11-02	Discuss in Heart Team complex obstructive coronary disease cases in whom revascularization is being considered.	SR
11-03	Calculate the STS score (https://acsdiskcalc.research.sts.org/) or EuroSCORE II (https://www.euroscore.org/) to estimate the risk of procedural mortality and/or 30-day mortality after CABG.	SR
11-04	Calculate the SYNTAX score (https://syntaxscore.org/) in patients with multivessel obstructive CAD to aid in the choice between PCI and CABG.	SR
11-05	Prefer CABG over PCI* in myocardial revascularization if: a) LMD with multivessel disease and low surgical risk b) MVD and diabetes. c) MVD and LVEF $\leq 35\%$.	SR
11-06	Prefer PCI over CABG in myocardial revascularization if: a) LMD with SYNTAX score ≤ 22 . b) MVD without diabetes, where PCI can provide similar revascularization completeness as CABG.	R

CABG, coronary artery bypass grafting; CAD, coronary artery disease; CIHD, chronic ischemic heart disease; LMD, left main disease; LVEF, left ventricular ejection fraction; MVD, multivessel disease; PCI, percutaneous coronary intervention; R, recommendation; SR, strong recommendation; STS, Society of Thoracic Surgeons; SYNTAX, synergy between PCI with taxus and cardiac surgery.

*Assuming acceptable surgical risk and availability of expertise.

Table 12. Recommendations for patients with heart failure and chronic ischemic heart disease.

No.	Guideline statement	Level of Recommendation
12-01	Enroll patients with ischemic HF in a multidisciplinary HF management program.	SR
12-02	Prescribe ACE-I/ARNI, MRA (eplerenone or spironolactone); SGLT2 inhibitor, and HF-specific beta-blocker (bisoprolol, carvedilol, nebivolol or sustained-release metoprolol succinate) to patients with HFrEF.	SR
12-03	Prescribe SGLT2 inhibitor (dapagliflozin or empagliflozin) to patients with HFmrEF or HFpEF.	SR
12-04	Prescribe MRA to patients with HFmrEF or HFpEF.	R (finerenone)
		Su (spironolactone)
12-05	An ARB is recommended in symptomatic patients with HFrEF unable to tolerate an ACE-I or ARNI.	SR
12-06	Replace ACE-I or ARB by ARNI in symptomatic HFrEF patients.	SR
12-07	Prescribe ivabradine to patients with HFrEF (LVEF $\leq 35\%$) and NYHA class II to III who are receiving GDMT, including maximally tolerated beta-blockers, and have sinus rhythm with a heart rate ≥ 70 bpm.	SR
12-08	Use diuretics in patients with HF and signs of congestion to alleviate symptoms.	SR
12-09	Use ICD in patients with symptomatic ischemic HF (NYHA II-III; LVEF $\leq 35\%$ despite ≥ 3 months of optimized GDMT, if expected to survive >1 year with good functional status.	SR
12-10	Use ICD therapy in patients who are at least 40 days post-MI, have an LVEF $\leq 30\%$, and have a prognosis of more than 1 year of survival.	SR
12-11	Use CRT in patients with symptomatic HF, sinus rhythm, LVEF $\leq 35\%$ despite GDMT, and QRS duration ≥ 150 ms with LBBB QRS morphology.	SR
12-12	Advanced therapies (mechanical circulatory support, heart transplantation) should be considered for eligible patients with end-stage heart failure refractory to other treatments.	R

ACE-I, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; ARNI, angiotensin receptor–neprilysin inhibitor; CRT, cardiac resynchronization therapy; GDMT, guideline-directed medical therapy; HF, heart failure; HFmrEF, heart failure with mildly reduced ejection fraction; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; ICD, implantable cardioverter defibrillator; LBBB, left bundle branch block; LVEF, left ventricular ejection fraction; MRA, mineralocorticoid receptor antagonist; NYHA, New York Heart Association; R, recommendation; SR, strong recommendation; SGLT2, sodium–glucose cotransporter-2; Su, suggestion.

Table 13. Recommendations for ischemia with non-obstructive coronary artery disease, microvascular angina, and vasospastic angina.

No.	Guideline statement	Level of Recommendation
13-01	Control all modifiable cardiovascular risk factors.	SR
13-02	Perform invasive coronary functional testing in selected persistently symptomatic patients with suspected ANOCA/INOCA.	R
13-03	Perform stress echocardiography with coronary flow velocity reserve in patients with persistent chest pain and non-obstructive CAD.	Su
13-04	Perform a resting 12-lead ECG and ambulatory ECG recording in patients with suspected vasospastic angina.	SR
13-05	In patients with suspected vasospastic angina and recurrent episodes of rest angina associated with ST-segment changes, invasive coronary angiography with provocative test is recommended.	SR
13-06	Prescribe calcium channel blockers for isolated vasospastic angina.	SR
13-07	Nitrates should be considered to prevent recurrent episodes in vasospastic angina.	SR
13-08	Avoid beta-blockers in patients with vasospastic angina.	DND
13-09	Prescribe combination therapy with nitrates, calcium channel blockers, and/or other antianginal drugs (ranolazine, trimetazidine) in patients with overlapping types of INOCA.	SR
13-10	Prescribe antianginal medications to reduce ischemia in microvascular angina with reduced coronary flow reserve.	SR
13-11	Prescribe ACE-Is in patients with endothelial dysfunction-related angina.	R

ACE-I, angiotensin-converting enzyme inhibitors; ANOCA, Angina with non-obstructive coronary arteries; CAD, coronary artery disease; ECG, electrocardiogram; INOCA, ischemia with non-obstructive coronary arteries; R, recommendation; SR, strong recommendation; Su, suggestion.

Table 14. Recommendations for refractory angina.

No.	Guideline statement	Level of Recommendation
14-01	Perform invasive coronary functional testing in patients with refractory angina.	SR
14-02	Use enhanced external counterpulsation in selected patients with refractory angina after failure of medical therapy.	Su
14-03	Use coronary sinus reducer in selected patients with debilitating angina and obstructive CAD with reversible ischemia in the left coronary artery territory, refractory to optimal strategies.	Su
14-04	Use spinal cord stimulation in selected patients with refractory angina after failure of medical therapy.	Su
14-05	Use extracorporeal cardiac shock wave therapy in selected patients with refractory angina after failure of medical therapy.	Su

CAD, coronary artery disease; SR, strong recommendation; Su, suggestion.

Table 15. Recommendations for other specific conditions.

No.	Guideline statement	Level of Recommendation
15-01	Prescribe a DOAC instead of VKA in patients with CIHD with a long-term indication for OAC, unless contraindicated (mechanical valvular prosthesis and rheumatic mitral stenosis).	SR
15-02	Promote hydration in patients with obstructive coronary disease and CKD to minimize contrast-induced nephropathy during PCI.	SR
15-03	Discuss the cases of CIHD and cancer in a multidisciplinary team including cardiology and oncology expertise due to complexity in the management of these patients.	SR
15-04	Prescribe potent statin with less interaction with antiretroviral drugs in HIV patients.	SR
15-05	Prescribe proton pump inhibitor in CIHD patients at high GI bleeding risk (<i>e.g.</i> , history of GI bleeding, concomitant use of NSAIDs/steroids, advanced age with multiple comorbidities, presence of dyspepsia, gastro-oesophageal reflux disease, helicobacter pylori infection, chronic alcohol use) treated with single antiplatelet therapy#.	R

To be continued on next page

15-06	Prescribe proton pump inhibitor in CIHD patients at increased GI bleeding risk (e.g., history of GI bleeding, concomitant use of NSAIDs/steroids, advanced age with multiple comorbidities, presence of dyspepsia, gastro-oesophageal reflux disease, helicobacter pylori infection, chronic alcohol use) treated with combined antithrombotic drugs.	SR
--------------	---	-----------

CAD, coronary artery disease; CIHD, chronic ischemic heart disease; CKD, chronic kidney disease; DOAC, direct oral anticoagulant; GI, gastrointestinal; HIV, human immunodeficiency virus; NSAIDs, non-steroidal anti-inflammatory drugs; OAC, oral anticoagulation; PCI, percutaneous coronary intervention; SR, strong recommendation; VKA, vitamin K antagonist.

Table 16. Recommendations for women with ischemic heart disease.

No.	Guideline statement	Level of Recommendation
16-01	Consider CIHD in women who present with chest pain or other symptoms such as jaw pain, epigastric discomfort, nausea, palpitations, or unexplained fatigue.	SR
16-02	Prescribe optimal medical therapy for IHD in both women and men.	SR
16-03	If obstructive CAD is not present, consider non-invasive or invasive imaging and/or coronary function testing to detect ANOCA.	R
16-04	Avoid systemic post-menopausal hormone therapy in women with CIHD, due to the absence of cardiovascular benefit and an increased risk of venous thromboembolism.	DND

ANOCA, angina with no obstructive coronary artery disease; CIHD, chronic ischemic heart disease; IHD, ischemic heart disease; INOCA, ischemia with no obstructive coronary artery disease; R, recommendation; SR, strong recommendation; Su, suggestion; DND, do not do.

Table 17. Recommendations for older people and frail patients.

No.	Guideline statement	Level of Recommendation
17-01	Monitor drug side effects, intolerance, drug-drug interactions, overdosing, and procedural complications in all patients with CIHD, and more strictly in older people.	SR
17-02	Consider all diagnostic and treatment including revascularization decisions based on symptoms, extent of ischemia, frailty, life expectancy, comorbidities, and patient preferences.	R
17-03	Acknowledge the procedural risks to guide shared decision-making, particularly in older people with complex coronary disease in whom revascularization is being considered.	SR

CIHD, chronic ischemic heart disease; R, recommendation; SR, strong recommendation.

Table 18. Recommendations about chronic ischemic heart disease, patients follow-up.

No.	Guideline statement	Level of Recommendation
18-01	Schedule periodic visits (<i>e.g.</i> , annual) to a general practitioner or cardiovascular healthcare professional, evaluate cardiovascular risk factor control and assess changes in risk status, disease status, and comorbidities, regardless of symptoms.	SR
18-02	Schedule the first follow-up appointment within 4-6 weeks after diagnosis or treatment modification, with subsequent visits every 3-6 months during the first year, and annual visits thereafter if stable.	SR
18-03	Provide a structured and individualized follow-up to all patients with CIHD to optimize long-term outcomes.	SR
18-04	Assess regularly the symptoms, lifestyle, medication adherence, and clinical status to guide ongoing therapy.	SR
18-05	Control the cardiovascular risk factors (blood pressure, LDL-C, glycemic status including HbA1c, adherence to smoking cessation, and optimize weight management) during follow-up, using evidence-based treatments and targets.	SR
18-06	Refer patients with CIHD to multidisciplinary cardiac rehabilitation is recommended to support secondary prevention and quality of life.	SR
18-07	Use digital tools, remote monitoring, or telehealth in selected patients to support long-term adherence.	R

CIHD, chronic ischemic heart disease; HbA1c, hemoglobin A1c; LDL-C, low-density lipoprotein cholesterol; R, recommendation; SR, strong recommendation.




Figure 1. Atherosclerotic Risk Factor Management in Ischemic Heart Disease.




Figure 2. Antithrombotic Therapy Recommendations in Ischemic Heart Disease.




Figure 3. Lifestyle Recommendations for Ischemic Heart Disease.

Conflict of interest

See Appendix.

Acknowledgements

The work towards this document is supported by Translational Medicine Academy, as well as by the iCARDIO Alliance and the ICARDIO Alliance Partner Societies: American Society for Preventive Cardiology, Asian Heart Society, Association of Physicians of India, Canadian Cardiovascular Society, Cardiac Society of Australia and New Zealand, Chinese Heart Failure Association, Ethiopian Society of Cardiac Professionals, Gulf Heart Association, Heart Failure Association of India, Heart Success Foundation, Honduran Association of Cardiology, Hypertension Society of India, Inter-American Society of Cardiology, International College of Cardiology, International Society of Nephrology, Italian Federation of Cardiology, Italian Heart Failure Association, National Heart Failure Committee (China), Obesity Canada, Pan-African Society of Cardiology, Roland Hetzer International Cardiothoracic & Vascular Surgery Society, Arrhythmia Alliance, Global Heart Hub, Heart Life Foundation.

We sincerely thank all those who participated in the public review for their valuable feedback and contributions. Their time, expertise, and insights have been instrumental in strengthening this document.

Author information

Task Force Member Affiliations:

Fausto J. Pinto, Faculdade de Medicina da Universidade de Lisboa, Centro Academico de Medicina de Lisboa, CCUL@RISE, Lisbon, Portugal; **Martha Gulati**, The Davis Women's Heart Center, Department of Cardiology, DeBakey Heart and Vascular Center, Houston Methodist, Houston, TX, USA; **Daniel Caldeira**, Centro de Estudos de Medicina Baseada na Evidência (CEMBE) and Centro Cardiovascular da Universidade de Lisboa (CCUL@RISE), Faculdade de Medicina, Universidade de Lisboa; Cardiology Department, Hospital Santa Maria, ULS Santa Maria, Lisbon, Portugal; **Clara K. Chow**, CPC Westmead Clinical Lead, Community Based Cardiac Services, Westmead Hospital, Sydney, NSW; Australian Stroke and Heart Research Accelerator (ASHRA), Monash University, Clayton, Victoria, Australia; **Luis Henrique Wolff Gowdak**, Heart Institute, University of São Paulo, São Paulo, Brazil; **Dipti Itchhaporia**, Hoag Memorial Hospital Presbyterian, Newport Beach, CA, University of California, Irvine, CA, USA; **Abdulla Shehab**, United Arab Emirates University, Al Ain, United Arab Emirates and Mediclinic Al Ain Hospital, Al Ain, United Arab Emirates; **Gurpreet Singh Wander**, Dayanand Medical College & Hospital, Ludhiana, Punjab, India; **Beth L. Abramson**, Paul Albrechtsen Chair in Cardiology, University of Toronto; Cardiologist, Preventive Cardiology & Women's CV Health, St. Michael's Hospital,

Toronto, Canada; **Takashi Akasaka**, Nishinomiya Watanabe Hospital, Nishinomiya, Japan; **Giuseppe Ambrosio**, National Institute for Cardiovascular Research – INRC, Bologna, Italy; **Alexandra Arias-Mendoza**, National Institute of Cardiology Ignacio Chavez, Mexico City, Mexico; **Otavio Berwanger**, Imperial College London, London, United Kingdom and The George Institute for Global Health UK, London, United Kingdom; **Anastase Dzudie**, Department of Internal Medicine and Subspecialties, Douala General Hospital, Douala, Cameroon; **Evangelos Giannitsis**, University Hospital Heidelberg, Heidelberg, Germany; **Rania Hammami**, Cardiology Department, Military University Hospital Of Sfax, Faculty of medicine of Sfax, University of Sfax, Tunisia; **Neil Johnson**, Global Heart Hub, Newcastle, Galway, Ireland; **Vijay Kunadian**, Translational and Clinical Research Institute Faculty of Medical Sciences, Newcastle University; Cardiothoracic Centre, Freeman Hospital, Newcastle upon Tyne, UK; **Renato D. Lopes**, Division of Cardiology, Duke University Medical Center, Duke Clinical Research Institute, Durham, NC, USA; **Athanasios Manolis**, Department of Cardiology, Metropolitan Hospital, Piraeus, Greece; **Girish Mathur**, Alka Diagnostic Centre, Kota, Rajasthan, India; **Giuseppe M.C. Rosano**, Department of Human Sciences and Promotion of Quality of Life, San Raffaele Open University of Rome; IRCCS San Raffaele, Rome, Italy; **Ana Salvati**, Clinical Model of Moron, Moron, Buenos Aires, Argentina; **Gregg W. Stone**, Icahn School of Medicine at Mount Sinai, New York, NY, USA; **Jean-Claude Tardif**, Montreal Heart Institute, Université de Montréal, Canada; **Ping Xie**, Gansu Provincial Hospital, Gantang, Fujian, China; **Jian Zhang**, Fuwai Hospital, CAMS and PUMC, Beijing, China; **Mohammad Zubaid**, Department of Medicine, Faculty of Medicine, Kuwait University, Kuwait.

Reviewer Affiliations:

William T. Abraham, Division of Cardiovascular Medicine and The Davis Heart and Vascular Research Institute, The Ohio State University (OSU) College of Medicine and OSU Wexner Medical Center, Columbus, OH, USA; **Wael Abuzeid**, Division of Cardiology, Department of Medicine, Queen's University, Kingston, Ontario, Canada; **Rasha Al-Bawardy**, King Faisal Cardiac Center, King Abdulaziz Medical City, Ministry of National Guard Health Affairs, Jeddah, Saudi Arabia and King Abdullah International Medical Research Center, Jeddah, Saudi Arabia and College of Medicine, King Saud Bin Abdulaziz University for Health Sciences, Jeddah, Saudi Arabia; **Thomas Alexander**, Division of Cardiology at Kovai Medical Center and Hospital, Coimbatore, Tamil Nadu, India; **Stefan D. Anker**, Department of Cardiology (CVK) of German Heart Center Charité; German Centre for Cardiovascular Research (DZHK) partner site Berlin, Charité Universitätsmedizin, Berlin, Germany; **John J. Atherton**, Department of Cardiology, Royal Brisbane and Women's Hospital and University of Queensland Faculty of Health, Medicine and Behavioural Sciences, Brisbane, QLD, Australia; **Andrea Baer**, Arrhythmia Alliance, Hilton Head Island, SC, USA; **Rakesh Bhadade**, Topiwala National Medical College And BYL Nair Charitable Hospital, Mumbai Central, Maharashtra, India; **William E. Boden**, Boston University School of Medicine,

Harvard Medical School, Boston, MA, USA; **Gabriela Borrayo Sanchez**, Universidad Nacional Autonoma de Mexico (UNAM); Mexican Institute of Social Security, Mexico City, Mexico; **Javed Butler**, Department of Medicine, University of Mississippi Medical Centre, Jackson, MS and Baylor Scott and White Research Institute, Dallas, TX, USA; **Edina Cenko**, Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy; **Edith H. Chavez**, Heart Institute, Clinica San Pablo, Surco, Lima, Peru; **Vijay Chopra**, Heart Failure Programme and Research, Max Super Specialty Hospital, Saket, New Dehli, India; **Andrew J.S. Coats**, Heart Research Institute, The University of Sydney, Sydney, NSW, Australia; **Marcelo Di Carli**, Brigham and Women's Hospital, Boston, MA, USA; **Jianzeng Dong**, Beijing Anzhen Hospital, Capital Medical University, Beijing, China; **Jan Fedacko**, Pavol Jozef Safarik University, Kosice, Slovakia and Kardiocentrum AGEL Saca, Kosice, Slovakia; **Gerasimos Filippatos**, National and Kapodistrian University of Athens School of Medicine, Athens University Hospital Attikon, Athens, Greece; **Abdoul Kane**, HOGGY (Hôpital Général de Grand Yoff), Dakar, Senegal; **Muhammad Shahzeb Khan**, Baylor Scott and White Research Institute, Dallas, TX-Baylor Scott and White, The Heart Hospital, Plano, TX, USA; **Pablos Lamelas**, Instituto Cardiovascular de Buenos Aires, Buenos Aires, Argentina; **Michael Lee**, Division of Cardiology, Department of Medicine, Queen Elizabeth Hospital, Hong Kong; **Haroldo Lopez**, Honduras Medical Center, Tegucigalpa, Honduras; **Angela H.E.M Maas**, Department of Cardiology, Radboud University Medical Center, Nijmegen, Netherlands; **Mpiko Ntekehe**, Division of Cardiology, Faculty of Health Sciences, University of Cape Town and Groote Schuur Hospital, Cape Town South Africa and South African Medical Research Council Extra Mural Unit on the Intersection of Infectious and Non-Communicable Diseases; **Pat O'Donnell**, Global Heart Hub, Newcastle, Galway, Ireland; **Gian Piero Perna**, Istituto Medico Palmatea, Fermo, Italy; **Miguel Quintana**, Instituto Cardiovascular y Pulmonar ICAP-LW Randall, Asunción, Paraguay; **Bagirath Raghuraman**, Narayana Institute of Cardiac Sciences, Narayana Health City, Bangalore, Karnataka, India; **Ruchit Shah**, K J Somaiya Hospital and Research Centre, Mumbai, Maharashtra, India; **Vladimir Ullauri**, Servicio de Cardiología, Hospital Metropolitano de Quito, Quito, Ecuador; **Sarah Zaman**, University of Sydney, Sydney Medical School (SMS), Westmead Applied Research Centre (WARC), Westmead, NSW, Australia; **Jose Luis Zamorano**, Department of Cardiology, University Hospital Ramón y Cajal, Madrid, Spain; **Yuhui Zhang**, Peking Union Medical College, Beijing, China; **Sheng-hua Zhou**, Department of Cardiology, The Second Xiangya Hospital of Central South University, Changsha, Hunan, China; **Shelley Zieroth**, University of Manitoba, St Boniface Hospital, Winnipeg, Canada; **Rodney Zimmermann**, Regina General Hospital, Regina, Saskatchewan, Canada; **Habib Gamra**, Faculty of Medicine, University of Monastir, Tunisia; **Maria Ines Sosa Liprandi**, Heart Failure, Cardiomyopathy and Pulmonary Hypertension Unit, Sanatorio Güemes, Buenos Aires, Argentina; **Juan-Carlos Kaski**, Cardiology Clinical Academic Group, St. George's University Hospitals NHS Trust and Royal Brompton Hospital, London, UK.

References

- Pinto FJ, Anker SD, Abraham WT, et al. The Global Implementation Guidelines Initiative: how to optimize cardio-renal-metabolic care worldwide. *Glob Cardiol* 2025;3:e68.
- Knuuti J, Wijns W, Achenbach S, et al. 2019 ESC guidelines for the diagnosis and management of chronic coronary syndromes. *Eur Heart J* 2020;41:407-77.
- Virani SS, Newby LK, Arnold SV, et al. 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA guideline for the management of patients with chronic coronary disease. *J Am Coll Cardiol* 2023;82:833-955.
- Vaduganathan M, Mensah GA, Turco JV, et al. The global burden of cardiovascular diseases and risk. *J Am Coll Cardiol* 2022;80:2361-71.
- Khan MA, Hashim MJ, Mustafa H, et al. Global epidemiology of ischemic heart disease: results from the Global Burden of Disease Study. *Cureus* 2020;12:e9349.
- Liang P, Zhang S, Yan M, et al. Trends and predictive research on the global burden of ischemic heart disease from 1990 to 2021: an analysis of the Global Burden of Disease Study 2021. *Front Public Health* 2025;13:1569179.
- Zhou X, Ruan W, Jie H, et al. Global trends in ischemic heart disease mortality from 1990 to 2021 and 2036 projections: insights from GBD 2021 data. *Glob Heart* 2025;20:92.
- Shi H, Xia Y, Cheng Y, et al. Global burden of ischaemic heart disease from 2022 to 2050: projections of incidence, prevalence, deaths, and disability-adjusted life years. *Eur Heart J Qual Care Clin Outcomes* 2025;11:355-66.
- Rittiphairoj T, Bulstra C, Ruampatana C, et al. The economic burden of ischaemic heart diseases on health systems: a systematic review. *BMJ Glob Health* 2025;10:e015043.
- Jespersen L, Abildstrøm SZ, Hvelplund A, et al. Symptoms of angina pectoris increase the probability of disability pension and premature exit from the workforce even in the absence of obstructive coronary artery disease. *Eur Heart J* 2013;34:3294-303.
- Vos T, Lim SS, Abbafati C, et al. Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. *Lancet* 2020;396:1204-22.
- Ferrari AJ, Santomauro DF, Aali A, et al. Global incidence, prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in 204 countries and territories and 811 subnational locations, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021. *Lancet* 2024;403:2133-61.
- Yang H, Ma Q, Han L, Liu H. A global prediction of cardiovascular disease from 2020 to 2030. *Front Cardiovasc Med* 2025;12:1462705.
- Bhupathiraju SN, Hu FB. Epidemiology of obesity and diabetes and their cardiovascular complications. *Circ Res* 2016;118:1723-35.
- United Nations Department of Economic and Social Affairs. World social report 2023: leaving no one behind in an ageing world. New York: United Nations; 2023.
- Gheorghe A, Griffiths U, Murphy A, et al. The economic burden of cardiovascular disease and hypertension in low- and middle-income countries: a systematic review. *BMC Public Health* 2018;18:975.
- Cenko E, Manfrini O, Fabin N, et al. Clinical determinants of ischemic heart disease in Eastern Europe. *Lancet Reg Health Eur* 2023;33:100698.
- Gouda HN, Charlson F, Sorsdahl K, et al. Burden of non-communicable diseases in sub-Saharan Africa, 1990-2017: results from the Global Burden of Disease Study 2017. *Lancet Glob Health* 2019;7:e1375-87.
- Prabhakaran D, Jeemon P, Sharma M, et al. The changing patterns of cardiovascular diseases and their risk factors in the states of India: the Global Burden of Disease Study 1990-2016. *Lancet Glob Health* 2018;6:e1339-51.
- Zubaid M, Rashed W, Alsheikh-Ali AA, et al. Disparity in ST-segment elevation myocardial infarction practices and outcomes in Arabian Gulf countries (Gulf COAST Registry). *Heart Views* 2017;18:41-6.
- Vrints C, Andreotti F, Koskinas KC, et al. 2024 ESC guidelines for the management of chronic coronary syndromes. *Eur Heart J* 2024;45:3415-537.
- Douglas PS, Hoffmann U, Patel MR, et al. Outcomes of anatomical versus functional testing for coronary artery disease. *N Engl J Med* 2015;372:1291-300.
- Douglas PS, Nanna MG, Kelsey MD, et al. Comparison of an initial risk-based testing strategy vs usual testing in stable symptomatic patients with suspected coronary artery disease: the PRECISE randomized clinical trial. *JAMA Cardiol* 2023;8:904-14.
- Kaur G, Oliveira-Gomes D, Rivera FB, Gulati M. Chest pain in women: considerations from the 2021 AHA/ACC chest pain guideline. *Curr Probl Cardiol* 2023;48:101697.
- Spitzer E, McFadden E, Vranckx P, et al. Critical appraisal of contemporary clinical endpoint definitions in coronary intervention trials: a guidance document. *JACC Cardiovasc Interv* 2019;12:805-19.
- Kronenberg F, Mora S, Stroes ESG, et al. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement. *Eur Heart J* 2022;43:3925-46.
- Gulati M, Levy PD, Mukherjee D, et al. 2021 AHA/ACC/AASE/CHEST/SAEM/SCCT/SCMR guideline for the evaluation and diagnosis of chest pain: executive summary. *J Am Coll Cardiol* 2021;78:2218-61.
- van der Ende MY, Siland JE, Snieder H, et al. Population-based values and abnormalities of the electrocardiogram in the general Dutch population: the LifeLines cohort study. *Clin Cardiol* 2017;40:865-72.
- Mark DB, Shaw L, Harrell FE, et al. Prognostic value of a treadmill exercise score in outpatients with suspected coronary artery disease. *N Engl J Med* 1991;325:849-53.
- SCOT-HEART Investigators. Coronary CT angiography and 5-year risk of myocardial infarction. *N Engl J Med* 2018;379:924-33.
- Xaplanteris P, Fournier S, Pijls NHJ, et al. Five-year outcomes with PCI guided by fractional flow reserve. *N Engl J Med* 2018;379:250-9.
- Göteborg M, Christiansen EH, Gudmundsdottir IJ, et al. Instantaneous wave-free ratio versus fractional flow reserve to guide PCI. *N Engl J Med* 2017;376:1813-23.
- Delgado-Lista J, Alcala-Diaz JF, Torres-Peña JD, et al. Long-term secondary prevention of cardiovascular disease with a Mediterranean diet and a low-fat diet (CORDIOPREV): a randomised controlled trial. *Lancet* 2022;399:1876-85.
- Laffond A, Rivera-Picón C, Rodríguez-Muñoz PM, et al. Mediterranean diet for primary and secondary prevention of cardiovascular disease and mortality: an updated systematic review. *Nutrients* 2023;15:3356.
- O'Donnell MJ, Yusuf S, Mente A, et al. Urinary sodium and potassium excretion and risk of cardiovascular events. *JAMA* 2011;306:2229-38.
- Sacks FM, Svetkey LP, Vollmer WM, et al. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. *N Engl J Med* 2001;344:3-10.

37. Rodrigues BS, Alves M, Duarte GS, et al. The impact of influenza vaccination in patients with cardiovascular disease: an overview of systematic reviews. *Trends Cardiovasc Med* 2021;31:315-20.
38. Caldeira D, Ferreira JJ, Costa J. Influenza vaccination and prevention of cardiovascular disease mortality. *Lancet* 2018;391:426.
39. Fröbert O, Götberg M, Erlinge D, et al. Influenza vaccination after myocardial infarction: a randomized, double-blind, placebo-controlled, multicenter trial. *Circulation* 2021;144:1476-84.
40. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. *N Engl J Med* 2015;373:2117-28.
41. Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. *N Engl J Med* 2016;375:311-22.
42. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. *N Engl J Med* 2023;389:2221-32.
43. Cosentino F, Grant PJ, Aboyans V, et al. 2019 ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. *Eur Heart J* 2020;41:255-323.
44. Cholesterol Treatment Trialists' (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials. *Lancet* 2010;376:1670-81.
45. Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes. *N Engl J Med* 2015;372:2387-97.
46. Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. *N Engl J Med* 2017;376:1713-22.
47. Schwartz GG, Steg PG, Szarek M, et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. *N Engl J Med* 2018;379:2097-107.
48. Bhatt DL, Steg PG, Miller M, et al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. *N Engl J Med* 2019;380:11-22.
49. Nissen SE, Lincoff AM, Brennan D, et al. Bempedoic acid and cardiovascular outcomes in statin-intolerant patients. *N Engl J Med* 2023;388:1353-64.
50. Ridker PM, Everett BM, Thuren T, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. *N Engl J Med* 2017;377:1119-31.
51. Tardif JC, Kouz S, Waters DD, et al. Efficacy and safety of low-dose colchicine after myocardial infarction. *N Engl J Med* 2019;381:2497-505.
52. Nidorf SM, Fiolet ATL, Mosterd A, et al. Colchicine in patients with chronic coronary disease. *N Engl J Med* 2020;383:1838-47.
53. Jolly SS, d'Entremont MA, Lee SF, et al. Colchicine in acute myocardial infarction. *N Engl J Med* 2025;392:633-42.
54. Ferrari R, Gowdak LHW, Padilla F, et al. The European Society of Cardiology 2024 guidelines on chronic coronary syndromes: a critical appraisal. *J Clin Med* 2025;14:1161.
55. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. *BMJ* 2002;324:71-86.
56. Byrne RA, Rossello X, Coughlan JJ, et al. 2023 ESC guidelines for the management of acute coronary syndromes. *Eur Heart J* 2023;44:3720-826.
57. Farkouh ME, Domanski M, Sleeper LA, et al. Strategies for multi-vessel revascularization in patients with diabetes. *N Engl J Med* 2012;367:2375-84.
58. Velazquez EJ, Lee KL, Jones RH, et al. Coronary-artery bypass surgery in patients with ischemic cardiomyopathy. *N Engl J Med* 2016;374:1511-20.
59. Mohr FW, Morice MC, Kappetein AP, et al. Coronary artery bypass graft surgery versus percutaneous coronary intervention in patients with three-vessel disease and left main coronary disease: 5-year follow-up of the randomised clinical SYNTAX trial. *Lancet* 2013;381:629-38.
60. De Bruyne B, Pijls NHJ, Kalesan B, et al. Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease. *N Engl J Med* 2012;367:991-1001.
61. Lee JM, Choi KH, Song YB, et al. Intravascular imaging-guided or angiography-guided complex PCI. *N Engl J Med* 2023;388:1668-79.
62. Ali ZA, Landmesser U, Maehara A, et al. Optical coherence tomography-guided versus angiography-guided PCI. *N Engl J Med* 2023;389:1466-76.
63. iCARTIO Alliance. Draft document for public consultation: iCARTIO Alliance Global Implementation Guidelines on Heart Failure 2025. *Glob Cardiol* 2024;2:e59.
64. Chopra V, Khan MS, Abdelhamid M, et al. iCARTIO Alliance Global Implementation Guidelines on Heart Failure 2025. *Heart Lung Circ* 2025;34:e55-82.
65. Ong P, Camici PG, Beltrame JF, et al. International standardization of diagnostic criteria for microvascular angina. *Int J Cardiol* 2018;250:16-20.
66. Beltrame JF, Crea F, Kaski JC, et al. The who, what, why, when, how and where of vasospastic angina. *Circ J* 2016;80:289-98.
67. Gallone G, Baldetti L, Tzanis G, et al. Refractory angina: from pathophysiology to new therapeutic nonpharmacological technologies. *JACC Cardiovasc Interv* 2020;13:1-19.
68. Amin AM, Khan U, Khlidj Y, et al. Efficacy and safety of coronary sinus reducer for refractory angina: a systematic review and meta-analysis of randomized controlled trials. *Coron Artery Dis* 2024. Epub ahead of print.
69. Caceres J, Atal P, Arora R, Yee D. Enhanced external counterpulsation: a unique treatment for the "no-option" refractory angina patient. *J Clin Pharm Ther* 2021;46:295-303.
70. Imran TF, Malapero R, Qavi AH, et al. Efficacy of spinal cord stimulation as an adjunct therapy for chronic refractory angina pectoris. *Int J Cardiol* 2017;227:535-42.
71. Ceccon CL, Duque AS, Gowdak LH, et al. Shock-wave therapy improves myocardial blood flow reserve in patients with refractory angina: evaluation by real-time myocardial perfusion echocardiography. *J Am Soc Echocardiogr* 2019;32:1075-85.
72. Weijing L, Ximin F, Jianying S, et al. Cardiac shock wave therapy ameliorates myocardial ischemia in patients with chronic refractory angina pectoris: a randomized trial. *Front Cardiovasc Med* 2021;8:664433.
73. de Silva R, Cheng K, Henry TD, et al. Refractory angina: mechanisms and stratified treatment in obstructive and non-obstructive chronic myocardial ischaemic syndromes. *Eur Heart J* 2025;46:3738-57.
74. Van Gelder IC, Rienstra M, Bunting KV, et al. 2024 ESC guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). *Eur Heart J* 2024;45:3314-414.
75. Bangalore S, Maron DJ, O'Brien SM, et al. Management of coronary disease in patients with advanced kidney disease. *N Engl J Med* 2020;382:1608-18.
76. Lyon AR, López-Fernández T, Couch LS, et al. 2022 ESC guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the Interna-

- tional Cardio-Oncology Society (IC-OS). *Eur Heart J* 2022;43:4229-361.
77. Grinspoon SK, Fitch KV, Zanni MV, et al. Pitavastatin to prevent cardiovascular disease in HIV infection. *N Engl J Med* 2023;389:687-99.
 78. Vogel B, Acevedo M, Appelman Y, et al. The Lancet women and cardiovascular disease Commission: reducing the global burden by 2030. *Lancet* 2021;397:2385-438.
 79. Hemal K, Pagidipati NJ, Coles A, et al. Sex differences in demographics, risk factors, presentation, and noninvasive testing in stable outpatients with suspected coronary artery disease. *JACC Cardio-vasc Imaging* 2016;9:337-46.
 80. Shaw LJ, Bairey Merz CN, Pepine CJ, et al. Insights from the NHLBI-sponsored Women's Ischemia Syndrome Evaluation (WISE) Study. *J Am Coll Cardiol* 2006;47:S4-20.
 81. Mehta LS, Beckie TM, DeVon HA, et al. Acute myocardial infarction in women. *Circulation* 2016;133:916-47.
 82. Gulati M, Shaw LJ, Bairey Merz CN. Myocardial ischemia in women: lessons from the NHLBI WISE Study. *Clin Cardiol* 2012;35:141-8.
 83. Appelman Y, Gulati M, Roeters van Lennep JE, et al. Cardiovascular disease in women: traditional and sex-specific risk factors. *Eur Heart J* 2025. Epub ahead of print.
 84. Afilalo J, Alexander KP, Mack MJ, et al. Frailty assessment in the cardiovascular care of older adults. *J Am Coll Cardiol* 2014;63:747-62.
 85. Fried LP, Tangen CM, Walston J, et al. Frailty in older adults: evidence for a phenotype. *J Gerontol A Biol Sci Med Sci* 2001;56: M146-57.
 86. Maron DJ, Newman JD, Anthopoulos R, et al. Guideline-directed medical therapy and outcomes in the ISCHEMIA trial. *J Am Coll Cardiol* 2025;85:1317-31.
 87. Ambrosio G, Gowdak LHW, Weiskopf RB, et al. Applicability of ischemic heart disease clinical practice guidelines in low- and middle-income countries. *Int J Cardiol* 2026. In press.